Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum
19 slides from Angiodynamics's conference presentation, Nov 19, 2020
Slide 1: Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum
11 | 19 | 2020 ANGIODYNAMICS Canaccord Genuity2020 Medical Technologies & Diagnostics Forum
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Strategic Transformation
PURSUIT OF LARGER MARKETSActive portfolio management enables us to compete in larger, growing markets relying on technology & innovation to produce measurable patient outcomes FOCUSED RESOURCE DEVELOPMENTResource deployment is focused in areas that offer best opportunities for success PORTFOLIO TRAN
Slide 4: Focused Transformation: U.S. Total Addressable Markets
4 FOCUSED TRANSFORMATIONU.S. Total Addressable Markets Our strategic initiative to become a growth company begins 2018 Launch of the Auryon System gives us access to the peripheral atherectomy market New Thrombectomy & NanoKnife System portfolio additions & indications increase market access $1.3B 0
Slide 5: Portfolio: Invest for Growth and Maintain Positioning
5 Diagnostic Catheters, Guidewires and Kits Vascular Access Catheters and Accessories Microwave & Radiofrequency Tumor Ablation Endovenous Laser Treatment Lung Biopsy Safety Radiation Treatment Stabilization Balloons INVEST FOR GROWTH MAINTAIN POSITIONING Thrombus Management Irreversible Electropora
Slide 6: Peripheral Atherectomy
PERIPHERAL ATHERECTOMY 11 | 19 | 2020 6
Slide 7: Auryon System catheters and laser technology
2.35 mmAspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR) 2.0 mmAspiration capability and indicated for Peripheral Atherectomy and ISR 1.5 mmIndicated for Peripheral Atherectomy Why wavelength mattersEach type of tissue interacts differently
Slide 8: Peripheral Atherectomy US Addressable Markets
PERIPHERAL ATHERECTOMYUS Addressable Markets MECHANICAL LASER $555M 23%1 1. Peripheral Vascular Devices Medtech 360 Market Analysis US 2017. (2016, December). Millennium Research Group, Inc. 77%1 ADAPTABLETreat all levels of calcificationa-cIndicated for in-stent restenosis*Treats above and below th
Slide 9: Thrombus Management
THROMBUS MANAGEMENT 11 | 19 | 2020 9
Slide 10: The AngioVac System Difference
The Difference The AngioVac System allows for the continuous aspiration of embolic material such as fresh, soft thrombi or vegetation from the venous systemUtilizing a self-expanding, nitinol reinforced funnel tipSimultaneously reinfusing the patient’s own filtered blood to limit procedural blood lo
Slide 11: Thrombus Management Planned Portfolio Additions & Addressable Markets
THROMBUS MANAGEMENTPlanned Portfolio Additions & U.S. Addressable Markets Expansion 11 PULMONARYEMBOLISM RIGHT HEART $3B DEEP VEIN THROMBOSIS $77M $1.3B $1.6B 2020 TAM FY 2021 FY 2022 FY 2023 FY 2025 FY 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 $140M $700M Multipurpose Mechani
Slide 12: Irreversible Electroporation
IRREVERSIBLE ELECTROPORATION 11 | 19 | 2020 12
Slide 13: NanoKnife irreversible electroporation
13 Probe placement Placement of probes around a target area provides effective treatment coverage a-d Electrical pulses cause pores to form within the cellular membrane leading to non-thermal cell death a-d Electrical field Decellularization Non-thermal Revascularization The NanoKnife System’s uniqu
Slide 14: Pancreas DIRECT IDE: Technology & Treatment
14 PANCREAS DIRECT IDETechnology & Treatment FDA Breakthrough DesignationFDA granted the NanoKnife System breakthrough therapy designation and AngioDynamics launched the DIRECT IDE. NanoKnife TechnologyThe NanoKnife System delivers a non-thermal ablation that preserves critical structures while term
Slide 15: Irreversible Electroporation Market Expansion Opportunities
15 540,400 Liver Cancer63,780 Patients Prostate Cancer 174,650 Patients Lung Cancer 228,150 Patients Kidney Cancer 73,820 Patients IRREVERSIBLE ELECTROPORATIONMarket Expansion Opportunities In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration
Slide 16: First Quarter FY2021 Results
First Quarter FY2021 Results (unaudited) $ in thousands (except per share data) Q1 FY2021 Q1 FY2020 YOY Change Revenue Vascular Interventions and Therapies Vascular Access Oncology United States International $70,21629,85728,10512,25454,10816,108 $66,04228,91323,15913,97052,93713,105 6.3%3.3%21.4%(1
Slide 17: Strategic Transformation
PURSUIT OF LARGER MARKETSActive portfolio management enables us to compete in larger, growing markets relying on technology & innovation to produce measurable patient outcomes FOCUSED RESOURCE DEVELOPMENTResource deployment is focused in areas that offer best opportunities for success PORTFOLIO TRAN
Slide 18: Peripheral Atherectomy References
18 **Peripheral Atherectomy References: a. Rundback J, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Novel laser-based catheter for peripheral atherectomy: 6-month results from the Eximo Medical B-Laser™ IDE study. Catheter Cardiovasc Interv. 2019;1-8. b. Shammas NW, Chandra P, Bro
Slide 19: AngioVac Indications for Use
AngioVac Cannula Indication for Use: The AngioVac Cannula is indicated for use as a venous drainage cannula and for removal of fresh, soft thrombi or emboli during extracorporeal bypass for up to 6 hours. | Contraindications: Contraindicated for patients with severe arterial or venous vascular disea
AngioDynamics — Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum on 6ix